Close Menu

NEW YORK (GenomeWeb) – Exact Sciences late Sunday said that it expects to report fourth quarter revenues of $86.9 million to $87.9 million, an increase of about 148 percent from Q4 2016.

The firm said it completed approximately 176,000 Cologuard colorectal cancer screening tests, 115 percent more than the year before. Nearly 11,000 health care providers ordered Cologuard for the first time during Q4.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.